Aurobindo Pharma rose 3.09% to Rs 767.20 at 10:31 IST on BSE after consolidated net profit rose 4.1% to Rs 432.40 crore on 14.1% growth in net operating income to Rs 3320.40 crore in Q1 June 2015 over Q1 June 2014.
The Q1 result was announced after market hours yesterday, 12 August 2015.
Meanwhile, the S&P BSE Sensex was up 118.62 points or 0.43% at 27,630.88.
On BSE, so far 2.21 lakh shares were traded in the counter as against average daily volume of 1.46 lakh shares in the past one quarter.
The stock hit a high of Rs 777 and a low of Rs 750 so far during the day. The stock had hit record high of Rs 796 on 7 August 2015. The stock had hit 52-week low of Rs 375.88 on 13 August 2014.
The stock had outperformed the market over the past one month till 12 August 2015, advancing 2.46% compared with Sensex's 0.54% fall. The scrip had also outperformed the market in past one quarter, surging 12.58% as against Sensex's 2.36% rise.
The large-cap pharma company has equity capital of Rs 58.40 crore. Face value per share is Re 1.
Aurobindo Pharma's sales from Formulations business rose 15.9% to Rs 2637.10 crore in Q1 June 2015 over Q1 June 2014. Sales from active pharmaceutical ingredients (APIs) business rose 7.9% to Rs 723 crore in Q1 June 2015 over Q1 June 2014.
Aurobindo Pharma, headquartered at Hyderabad, manufactures generic pharmaceuticals and active pharmaceutical ingredients.
Powered by Capital Market - Live News
